Live news related to NANOBIOTIX stock (FR0011341205): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The biotechnology stock continues its retreat since Friday, losing over 7% at the start of the session.
This week, Nanobiotix's stock value experienced a significant decline at the Paris Stock Exchange, amidst the anticipated postponement of clinical res…
Nanobiotix shows a significantly negative performance this midday Friday, with the stock dropping 8.46% to trade at €16.24, down from €17.74 at close …
Nanobiotix has announced the completion of the clinical trial sponsorship transfer of NANORAY-312 to Johnson & Johnson, according to a statement relea…
NANOBIOTIX stock ended Thursday, October 23, with a decrease of 7.70%, at €17.74, extending a more pronounced correction over the last seven days. Fol…
Nanobiotix shares ended the session on Wednesday, October 22, down by 5.09%, at 19.22 euros. This correction occurs in a context of increased volatili…
The biotechnology company's stock ended the session on Tuesday, October 21 at €20.25, down 7.53% from the previous close of €21.90. This correction oc…
The biotechnology company's stock closed at 22.30 euros on Friday, down 6.11% in a slightly declining Paris market. This correction follows a spectacu…
The French biotech company closed the trading session on Thursday, October 9th at €23.90, up by 7.66% from the previous day. This latest increase exte…
